Bilateral corneal ulceration in ocular graft-versus-host disease

William Stevenson
Hasanain Shikari
Ujwala S Saboo
Francisco Amparo
Reza Dana

Cornea Service, Massachusetts Eye and Ear Infirmary, Boston, MA, USA

Purpose: To report on corneal ulceration in ocular graft-versus-host disease (GVHD).

Methods: This was a retrospective, observational case series investigating corneal ulceration and perforation in a cohort of ocular GVHD patients seen between June 2007 and October 2012.

Results: Four of 243 ocular GVHD patients developed corneal ulcerations attributable to ocular GVHD, and all four cases involved bilateral corneal ulceration. The median length of time from the diagnosis of ocular GVHD to the diagnosis of the first corneal ulceration was 317 days (range 168–434). The median length of time between the diagnosis of corneal ulceration in each patient’s first and second eye was 248 days (range 9–645). Outcomes varied from complete resolution with medical treatment to corneal perforation necessitating penetrating keratoplasty. In cases of corneal perforation, the median length of time from the diagnosis of corneal ulceration to perforation was 10 days (range 0–20). Common clinical features included: centrally or paracentrally located ulcerations and perforations, concomitant dry eye, and the use of topical or systemic corticosteroids.

Conclusion: Frequent follow-up and bilateral monitoring are highly recommended in cases of ocular GVHD-associated stromal thinning, as bilateral involvement or rapid progression to corneal perforation can occur.

Keywords: graft-versus-host disease, ocular graft-versus-host disease, corneal ulceration, corneal perforation

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) is used to treat a variety of acquired and congenital hematological disorders. However, allogeneic HSCT can give rise to graft-versus-host disease (GVHD), a significant cause of morbidity and mortality in allogeneic HSCT recipients. Historically, GVHD has been classified as either acute or chronic based on an arbitrary time point of 100 days posttransplantation. Classification criteria have since been developed that more accurately reflect the signs and symptoms associated with each subtype of GVHD. Chronic GVHD arises in up to 80% of allogeneic HSCT recipients who survive beyond 100 days posttransplantation. Diagnostic or distinctive manifestations of chronic GVHD can occur in the skin, mouth, gastrointestinal tract, genitals, lungs, musculoskeletal system, and eyes.

Ocular manifestations occur in up to 80% of chronic GVHD patients. Although chronic GVHD can theoretically affect any ocular structure, it generally targets components of the ocular surface system, including the cornea, conjunctiva, eyelid, lacrimal glands, meibomian glands, and lacrimal drainage system. The distinctive manifestations of ocular GVHD include new-onset dry, gritty, or painful eyes, confluent areas...
of punctate keratopathy, and cicatricial conjunctivitis. These ocular manifestations have the potential to impact quality of life negatively and hinder the performance of activities of daily living. In extreme cases, ocular GVHD can give rise to sight-threatening complications, such as corneal ulceration and perforation. Herein, we present four cases of bilateral corneal ulceration associated with ocular GVHD.

Materials and methods
This was a retrospective, observational case series investigating the occurrence of ocular GVHD-associated corneal ulceration in a cohort of patients seen by the Cornea Service at the Massachusetts Eye and Ear Infirmary in Boston, MA between June 2007 and October 2012. According to the National Institutes of Health, the diagnosis of ocular GVHD requires either new-onset ocular dryness with a mean Schirmer’s score of ≤5 mm or new-onset clinical signs of dry eye with a Schirmer’s score of 6–10 mm occurring in a patient with manifestations of chronic GVHD in at least one other organ system. The following variables were calculated: 1) the incidence of corneal ulceration secondary to ocular GVHD, 2) the median age at presentation for corneal ulceration, 3) the median length of time from HSCT to the diagnosis of ocular GVHD, 4) the median length of time from the diagnosis of ocular GVHD to the diagnosis of the first corneal ulceration, 5) the median length of time between the diagnosis of corneal ulceration in each patient’s first and second eye, and 6) the median length of time from corneal ulceration to perforation. Results are presented as the median (range). This study adhered to the principles of the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board at Massachusetts Eye and Ear Infirmary.

Results
Patient characteristics
A total of 243 ocular GVHD patients were seen by the Cornea Service at Massachusetts Eye and Ear Infirmary between June 2007 and October 2012. Four of 243 ocular GVHD patients (1.6%) developed corneal ulcerations attributable to ocular GVHD, and all four of these cases involved bilateral corneal ulceration. Patient demographics and clinical characteristics are summarized in Table 1. The median age was 46 years (range 28–59) at the time of presentation for each patient’s first corneal ulceration. The underlying hematological malignancies were varied, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and non-Hodgkin’s lymphoma (NHL). The median length of time from HSCT to the diagnosis of ocular GVHD was 446 days (range 115–4897). The median length of time from the diagnosis of ocular GVHD to the diagnosis of the first corneal ulceration was 317 days (range 168–434). The median length of time between the diagnosis of corneal ulceration in the first and second eye was 248 days (range 9–645). Two patients experienced corneal perforations; the median length of time from the diagnosis of corneal ulceration to perforation was 10 days (range 0–20).

Case 1
A 53-year-old man presented complaining of dryness, redness, photophobia, and fluctuating visual acuity that began shortly after he underwent cataract surgery. The patient’s medical history was significant for ALL, necessitating allogeneic HSCT that resulted in ocular GVHD. At presentation, ocular examination revealed a 4.5 × 9.0 mm inferoentral area of stromal thinning in the patient’s left (first) eye. The affected eye was treated with lubricating eye drops, prophylactic antibiotics, corticosteroids, and a sutureless amniotic membrane. However, the corneal ulceration perforated, necessitating penetrating keratoplasty with temporal tarsorrhaphy. The patient returned 1 year later, reporting a decrease in visual acuity, ocular pain, and redness. Ocular examination revealed a 3.5 × 2.2 mm paracentral area of stromal thinning in the same (first) eye. The patient was treated with lubricating eye drops, prophylactic antibiotics, corticosteroids, and a therapeutic contact lens. The ulcer resolved over the next several weeks, leaving behind a small scar with thinning and neovascularization. The patient returned several weeks later, complaining of irritation and blurred vision. Ocular examination revealed a 2.2 mm² area of stromal thinning in the right (second) eye. The patient was treated with lubricating eye drops, prophylactic antibiotics, corticosteroids, and a therapeutic contact lens. The corneal ulceration in the patient’s right (second) eye resolved. However, the patient returned with another corneal perforation in his left (first) eye located in an area of residual thinning. Corneal glue was placed, and a therapeutic penetrating keratoplasty was performed. At the patient’s last follow-up visit, his best corrected visual acuity (BCVA) was 20/30 in his right eye and 20/400 in his left eye.

Case 2
A 28-year-old woman presented complaining of dryness, irritation, photophobia, and a “gush” of fluid from her right (first) eye that occurred 5 days before she presented to our clinic. The patient’s past medical history was significant for herpes simplex virus keratitis in her right eye, AML treated...
Clinical Ophthalmology 2013:7

Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age/sex</td>
<td>53/male</td>
<td>28/female</td>
<td>59/female</td>
</tr>
<tr>
<td>Underlying disease</td>
<td>ALL</td>
<td>AML</td>
<td>CML</td>
</tr>
<tr>
<td>Conditioning regimen</td>
<td>Myeloablative</td>
<td>Myeloablative</td>
<td>Myeloablative</td>
</tr>
<tr>
<td>Donor sex/relation</td>
<td>Male/unrelated</td>
<td>Male/unrelated</td>
<td>Male/related</td>
</tr>
<tr>
<td>Donor HLA status</td>
<td>Matched 6/6</td>
<td>Matched 5/6</td>
<td>Matched 5/6</td>
</tr>
<tr>
<td>Transplant type</td>
<td>PBST</td>
<td>PBST</td>
<td>BMT</td>
</tr>
<tr>
<td>GVHD prophylaxis</td>
<td>Tacrolimus,</td>
<td>Prednisolone,</td>
<td>Cyclosporine</td>
</tr>
<tr>
<td></td>
<td>sirolimus</td>
<td>sirolimus</td>
<td></td>
</tr>
<tr>
<td>GVHD manifestations</td>
<td>Skin, liver,</td>
<td>Liver, lungs,</td>
<td>Eyes</td>
</tr>
<tr>
<td></td>
<td>eyes</td>
<td>eyes</td>
<td>eyes</td>
</tr>
<tr>
<td>Days from HSCT to ocular</td>
<td>447</td>
<td>445</td>
<td>4,897</td>
</tr>
<tr>
<td>GVHD diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days from HSCT to ulceration</td>
<td>OD: 1,287</td>
<td>OD: 670</td>
<td>OD: 5,065</td>
</tr>
<tr>
<td></td>
<td>OS: 881</td>
<td>OS: 1,315</td>
<td>OS: 5,155</td>
</tr>
<tr>
<td>Days from HSCT to perforation</td>
<td>OD: 670</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Culture results</td>
<td>Staphylococcus</td>
<td>Hemolytic streptococci</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>aureus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual acuity at presentation</td>
<td>OD: 20/100</td>
<td>OD: 20/200</td>
<td>OD: 20/40</td>
</tr>
<tr>
<td></td>
<td>OS: CF @ 1 foot</td>
<td>OS: 20/300</td>
<td>OS: 20/100</td>
</tr>
<tr>
<td>Visual acuity at last follow-up visit</td>
<td>OD: 20/30</td>
<td>OD: 20/30</td>
<td>OD: 20/30</td>
</tr>
<tr>
<td>Duration of topical corticosteroids before ulceration</td>
<td>Unknown</td>
<td>OD: 2 weeks</td>
<td>OD: NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of oral corticosteroids before ulceration</td>
<td>2 months</td>
<td>15 months</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin’s lymphoma; CML, chronic myeloid leukemia; TBI, total body irradiation; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; PBST, peripheral blood stem cell transplantation; BMT, bone marrow transplantation; GVHD, graft-versus-host disease; OD, right eye; OS, left eye; CF, count fingers; NA, not applicable.

Case 3
A 59-year-old woman presented complaining of dryness and irritation. The patient’s past medical history was significant for CML treated with allogeneic HSCT that resulted in ocular GVHD. Ocular examination revealed a 1.0 × 1.1 mm inferonasal epithelial defect with stromal thinning without any signs of infection in her right (first) eye. The patient was treated with lubricating eye drops, prophylactic antibiotics, corticosteroids, and a therapeutic contact lens. The corneal ulceration healed over the next several months, leaving behind minimal residual thinning. Shortly thereafter, the patient returned with a 1 mm inferonasal epithelial defect with stromal thinning without any signs of infection in her left (second) eye. In addition to the standard therapy, she was prescribed topical anakinra (Kineret®; Swedish Orphan Biovitrum, Stockholm, Sweden), and her signs and symptoms resolved with minimal residual thinning. The patient’s BCVA was 20/30 in her right eye and 20/30 in her left eye at her last follow-up visit.

Case 4
A 39-year-old man presented complaining of blurred vision and photophobia. The patient’s past medical history was significant for NHL treated with allogeneic HSCT that resulted in ocular GVHD, and an episode of stromal thinning. The patient presented complaining of blurred vision without any associated pain. Ocular examination revealed a 2 mm² area of...
stromal thinning in the patient’s right (first) eye. Lubricating
eye drops and cyclosporine (Restasis®; Allergan, Irvine, CA,
USA) were increased, prophylactic antibiotics were initiated,
and a therapeutic contact lens was placed. Shortly after this
visit, the patient was admitted to Massachusetts General
Hospital for systemic manifestations of chronic GVHD. At
the time of admittance, the patient complained of severe pain,
decreased visual acuity, and photophobia. Ocular examina-
tion revealed a 3.6 × 4.4 mm inferocentral area of stromal
thinning in the patient’s right (first) eye. The corneal thinning
continued to increase in the patient’s right (first) eye, and a
central epithelial defect began to form in his left (second)
eye. The epithelial defect in the left (second) eye rapidly
progressed to stromal melting, necessitating treatment with
a scleral lens. Following placement of the scleral lens, the
patient reported increased comfort and his BCVA improved
to 20/80 in his left eye; however, he died several days later
from complications of systemic GVHD.

Discussion
The mechanisms underlying corneal ulceration and perfora-
tion in ocular GVHD are incompletely understood. GVHD
occurs when donor-derived immune cells recognize and
attack recipient tissues. Donor-derived T cells and innate
immune cells have been identified in ocular specimens
obtained after allogeneic HSCT, and T cells predominate in
the inflammatory lesions associated with ocular GVHD. T-cell-associated cytokines and chemokines have been
identified in the tears and ocular surface of ocular GVHD
patients. Perforated corneal specimens from patients with
chronic GVHD have been shown to contain T cells and
macrophages, apoptotic epithelial cells and keratocytes,
and intense expression of matrix metalloproteinase. Pretreatment regimens that involve radiation or chemo-
therapy can damage ocular tissues, and ocular GVHD has
been associated with epithelial–mesenchymal transition and
fibrosis. Dry eye is the most common ocular manifesta-
tion of chronic GVHD, and severe dry eye has been associated
with corneal epitheliopathy, ulceration, and perforation. Chronic inflammation-induced corneal neuropathy or limbal
stem cell deficiency may also contribute to corneal ulceration
and perforation in ocular GVHD.

Four of 243 ocular GVHD patients developed corneal
ulcerations attributable to ocular GVHD, yielding an
incidence of 1.6% in this patient population. Given that
Massachusetts Eye and Ear Infirmary is a tertiary referral
center it is unclear how representative this patient popula-
tion is of the ocular GVHD population at large. The cases
presented herein share a number of similarities that may
provide insight into the pathogenesis of corneal ulceration
in ocular GVHD. For example, bilateral involvement
occurred in all of the cases, highlighting the systemic
immune etiology of GVHD. Bilateral corneal ulcers have
been described in a variety of immune-mediated disorders,
including Sjögren’s syndrome and rheumatoid arthritis. Severe dry eye was present in all of the cases, and severe
dry eye has been associated with corneal ulceration and
perforation. The corneal ulcerations observed in the pres-
cent study occurred in central or paracentral locations,
suggestive of neurotrophic ulceration or limbal stem cell
deficiency. Unsurprisingly, all of the cases involved the use
of topical or systemic corticosteroids, either prior to or at
the time of corneal ulceration. Corticosteroids, particularly
topical corticosteroids, have been linked to corneal thinning,
ulceration, and perforation. However, corticosteroids are
frequently used to promote quiescence in cases of severe
ocular surface inflammation; hence, corticosteroid use may
be a marker of heightened disease severity.

Despite therapeutic intervention, two of the corneal
ulcerations progressed to perforation, and all four cases
involved bilateral corneal ulceration. These findings suggest
that frequent follow-up and bilateral ocular examinations
are essential, as bilateral involvement or rapid progression
to corneal perforation can occur. Although ocular GVHD
undoubtedly contributed to all of the cases presented herein,
the pathogenesis of these corneal ulcerations and perfora-
tions was likely multifactorial. For example, several of the
patients underwent cataract surgery immediately before they
developed corneal ulcerations, suggesting that the trauma
and inflammation associated with ocular surgery may pre-
dispose these patients to developing corneal ulcerations.
Corticosteroids should be used judiciously; while corticos-
steroids can decrease ocular surface inflammation, they may
also increase the risk of corneal ulceration or perforation.
Topical cyclosporine has proven beneficial in the treatment
of ocular GVHD-associated dry eye, and cyclosporine is
currently being investigated as a prophylactic treatment for
the prevention of ocular GVHD. Topical interleukin 1
inhibition has shown promise in the treatment of dry eye
disease; however, further study is needed before this can be
routinely recommended for ocular GVHD. Cases of ocular
GVHD-associated corneal ulceration should be treated with
prophylactic antibiotics, and cultures should be performed
as needed to rule out infection. Corneal ulcerations may also
benefit from the use of aggressive lubrication and therapeutic
contact lenses.
The surgical management of a corneal perforation is largely dictated by the size of the perforation and the presence or absence of anterior-chamber leakage. Corneal transplantation in the setting of ocular GVHD is considered high-risk because of the intense inflammation at the ocular surface. A small perforation may benefit from the use of a bandage contact lens, cyanoacrylate tissue adhesive, or multilayer amniotic membrane transplantation; penetrating keratoplasty is generally deferred until the eye is quiet, as the benefits may be offset by the increased risk of graft failure. A large perforation, however, often requires full-thickness tectonic corneal grafting. Further investigation will be necessary to elucidate fully the pathogenesis of ocular GVHD, improve diagnostic and grading criteria, identify risk factors for corneal ulceration and perforation, and provide evidence-based treatment guidelines.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Li HW, Sykes M. Emerging concepts in haematopoietic cell transplan-
2. Lee SJ, Flowers ME. Recognizing and managing chronic graft-
3. Filipovic AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical tri-
sion in chronic GVHD of the conjunctiva. Bone Marrow Transplant. 2010;45(8):1340–1346.
17. Yeh PT, Hou YC, Lin WC, Wang IJ, Hu FR. Recurrent corneal perfora-
tion and acute calcareous corneal degeneration in chronic graft-versus-
24. Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allo-
29. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, ran-
30. Rao SN, Rao RD. Efficacy of topical cyclosporine 0.05% in the treat-